<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02798185</url>
  </required_header>
  <id_info>
    <org_study_id>H-34799</org_study_id>
    <secondary_id>U01NS093334</secondary_id>
    <nct_id>NCT02798185</nct_id>
  </id_info>
  <brief_title>The DIAGNOSE-CTE Research Project</brief_title>
  <acronym>DIAGNOSE-CTE</acronym>
  <official_title>Diagnostics, Imaging And Genetics Network for the Objective Study and Evaluation of Chronic Traumatic Encephalopathy (DIAGNOSE CTE) Research Project</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Banner Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>New York University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Cleveland Clinic</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Neurological Disorders and Stroke (NINDS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Boston University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study to develop methods of diagnosing chronic traumatic encephalopathy (CTE)
      during life, as well as to examine possible risk factors for this neurodegenerative disease.
      One component of this study is the use of an investigational PET scan radio tracer to detect
      abnormal tau protein in the brain.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Chronic Traumatic Encephalopathy (CTE) is a neurodegenerative disease characterized by a
      distinct deposition of phosphorylated tau (p-tau) in neurons and astrocytes in a pattern that
      is unique from other tauopathies, including Alzheimer's disease (AD). Although the
      neuropathological features of CTE have become further clarified in recent years, the clinical
      presentation of CTE is still not well characterized. Diagnostic criteria have only recently
      been published and lack validation.

      Neuroimaging and fluid biomarkers developed for the diagnosis of other neurodegenerative
      diseases have only been used in preliminary studies of individuals at high risk for CTE,
      namely athletes with histories of significant exposure to repetitive head impacts (RHI), such
      as former football players and boxers. There is thus an urgent need to develop accurate
      methods for detecting and diagnosing CTE during life so that effective interventions for
      prevention and treatment can be developed. Moreover, though a history of RHI is a necessary
      risk factor for CTE, it alone is not sufficient. There is a need to understand what specific
      aspects of RHI exposure places an individual at increased risk for CTE and to examine
      potential genetic polymorphisms that modify that risk.

      To address these needs, the investigators are conducting a multidisciplinary, multicenter,
      longitudinal study of former NFL and varsity college football players (with and without
      symptoms), and a control group of asymptomatic same-age men without any history of RHI
      exposure, traumatic brain injury or military service. Subjects will be seen at 1 of 4
      participating study sites in Boston; Las Vegas, ; New York; and Scottsdale/Phoenix . Subjects
      will undergo a baseline evaluation and a 3 year follow-up evaluation (currently former
      college players will not complete the follow-up evaluation). Each evaluation will be take
      place over a 3 day period and consist of the following procedures/tests: neurocognitive
      testing, determination of functional independence, neuropsychiatric examination (with
      measures of mood and behavior), neurological assessment (motor, headache, postural
      stability), neuroimaging (including structural, diffusion, functional, biochemical, and
      molecular imaging), lumbar punctures (for Cerebrospinal Fluid (CSF) biomarkers), blood draws
      (for blood biomarkers and DNA), and saliva samples (for biomarkers).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2016</start_date>
  <completion_date type="Anticipated">July 2023</completion_date>
  <primary_completion_date type="Anticipated">July 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Neuroimaging Positron Emission Tomography for Amyloid Biomarker</measure>
    <time_frame>One-Time</time_frame>
    <description>Subjects will undergo a Florbetapir Positron Emission Tomography (PET) scan.
The Outcome Measurement for the Florbetapir PET Scan will be &quot;elevated&quot; or &quot;not elevated&quot;</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Fluid Biomarkers</measure>
    <time_frame>3 Years</time_frame>
    <description>The following Biospecimens will be collected from subjects:
Saliva, blood and cerebral spinal fluid (CSF). CSF will be collected by a lumbar puncture (spinal tap) Fluid biomarkers will be analyzed for the in vivo detection of CTE.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Neuropsychiatric and Neurocognitive Tests</measure>
    <time_frame>3 years</time_frame>
    <description>Composite scores (presented as z scores) based on factor analytic methodology in the following domains:
Mood
Behavior Regulation
Attention, Information Processing and Psychomotor Speed
Executive Functioning
Verbal Memory
Visual Memory
Visual-Spatial Ability
Language</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Neurological Evaluation</measure>
    <time_frame>3 years</time_frame>
    <description>Subjects will undergo The Movement Disorder Society's Unified Parkinson's Disorders Rating Scale (MDS-UPDRS) Neurological Evaluation by a physician. This evaluation will be analyzed to characterize the clinical presentation of CTE.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Magnetic Resonance Imagining Biomarkers</measure>
    <time_frame>3 years</time_frame>
    <description>Subjects will undergo Diffuser Tension Imaging (dti) and Functional MRI scans, to assess structural brain volumetrics, fractional anisotropy, radial diffusivity, and changes in brain activity associated with blood flow.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Neuroimaging Positron Emission Tomography for Tau Biomarker</measure>
    <time_frame>3 years</time_frame>
    <description>Subjects will undergo an Investigational drug: AV1451 Positron Emission Tomography (PET) scan.
The Outcome Measurement for AV1451 PET scan will be Standardized Uptake Value Ratio (SUVR) of Tau.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Magnetic Resonance Spectroscopy Biomarkers</measure>
    <time_frame>3 years</time_frame>
    <description>Subject will also undergo Magnetic Resonance Spectroscopy (MRS) to measure glutamate, glutamine and myoinosotol.</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Chronic Traumatic Encephalopathy</condition>
  <arm_group>
    <arm_group_label>Former NFL Players</arm_group_label>
    <description>120 former National Football League players with and without reported cognitive, mood and behavior symptoms will be enrolled in this study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Former College Football Players</arm_group_label>
    <description>60 former college football players with and without reported cognitive, mood and behavior symptoms will be enrolled in this study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <description>60 asymptomatic same-age men without any history of participation in contact sports, military service, or traumatic brain injury will be enrolled in this study.</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Biospecimen samples to be collected include: saliva, blood and cerebral spinal fluid (CSF)
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Former National Football League Players, Former Varsity Level College Football Players,
        Healthy Controls
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Former NFL Players:

          -  English as primary language

          -  No MRI or Lumber Puncture (LP) contraindications

          -  Have played â‰¥12 years of organized football (including =&gt;3 in college and =&gt;3 seasons
             in the NFL)

          -  Must have played one of following positions offensive lineman, defensive lineman,
             linebacker, tight end, wide receiver, running back, or defensive back.

          -  Agree to provide name and contact information of a study partner who will complete
             questionnaires regarding subject's mood, behavior, thinking and cognitive function
             should the subject enroll in the study.

        Former Collegiate Football Players

          -  English as primary language

          -  No MRI or Lumber Puncture (LP) contraindications

          -  Must have played =&gt;6 years of organized football (with =&gt; 3 years at the college
             level, but no organized football or other contact sport following college.)

          -  Must have played one of following positions offensive lineman, defensive lineman,
             linebacker, tight end, wide receiver, running back, or defensive back.

          -  No military service

          -  Agree to provide name and contact information of a study partner who will complete
             questionnaires regarding subject's mood, behavior, thinking and cognitive function
             should the subject enroll in the study.

        Control Group

          -  English as primary language

          -  No MRI or Lumber Puncture (LP) contraindications

          -  No history of organized contact sports or known traumatic brain injury (TBI) and/or
             moderate/severe concussions

          -  No history of participation in any of the following organized sports at any level:
             football, hockey, rugby, soccer, lacrosse, wrestling, boxing, gymnastics, martial
             arts, and kickboxing.

          -  No military service.

          -  Must have BMI &gt;=24

          -  Agree to provide name and contact information of a study partner who will complete
             questionnaires regarding subject's mood, behavior, thinking and cognitive function
             should the subject enroll in the study.

          -  Must be asymptomatic when screened by telephone.

        Former NFL and Varsity Collegiate Football Players Exclusion Criteria:

          -  If they do not meet inclusion criteria

          -  If they have a history of clinical stroke confirmed on neuroimaging

          -  If they have vision or hearing impairment significant enough to compromise
             neuropsychological testing

          -  If they are unable to undergo MRI/PET Scan

          -  If they are unable to travel to one of 4 study sites to participate

          -  If they cannot provide the name and contact information of an eligible study partner

          -  If they are taking blood thinners that would make LP unsafe

          -  If they do not agree to all study tests and procedures

          -  If they are unable to consent to study procedures

        Control Group Exclusion:

          -  If they do not meet inclusion criteria

          -  If they have vision or hearing impairment significant enough to compromise
             neuropsychological testing

          -  If they are unable to undergo MRI/PET Scan

          -  If they are unable to travel to one of 4 study sites to participate

          -  If they cannot provide the name and contact information of an eligible study partner

          -  If they report any cognitive concerns or dementia during screening process

          -  If they are unable to consent to study procedures
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert A Stern, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Boston University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Robert A Stern, PhD</last_name>
    <phone>617-414-1195</phone>
    <email>bobstern@bu.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Courtney Diamond, BS</last_name>
    <phone>617- 414-1126</phone>
    <email>cdiamond@bu.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Boston University School of Medicine</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02118</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Taylor Platt</last_name>
      <phone>617-414-1193</phone>
      <email>tplatt@bu.edu</email>
    </contact>
    <contact_backup>
      <last_name>Shannon Conneely, BA</last_name>
      <phone>6174148389</phone>
      <email>sconn@bu.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.diagnosecte.com</url>
    <description>Study website</description>
  </link>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 20, 2016</study_first_submitted>
  <study_first_submitted_qc>June 13, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 14, 2016</study_first_posted>
  <last_update_submitted>August 3, 2017</last_update_submitted>
  <last_update_submitted_qc>August 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 4, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Boston University</investigator_affiliation>
    <investigator_full_name>Robert A. Stern</investigator_full_name>
    <investigator_title>Primary Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Diseases</mesh_term>
    <mesh_term>Brain Injuries, Traumatic</mesh_term>
    <mesh_term>Dementia</mesh_term>
    <mesh_term>Chronic Traumatic Encephalopathy</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>De-identified data will be shared with FITBIR and other data sharing portals</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

